Skip Nav Destination
Issues
1 June 2000
ISSN 1078-0432
EISSN 1557-3265
Editorial
Review
Advances in Brief
Priming Tissue-specific Cellular Immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer1
Patrick A. Burch; Jami K. Breen; Jan C. Buckner; Dennis A. Gastineau; Judith A. Kaur; Reiner L. Laus; Douglas J. Padley; Madhusudan V. Peshwa; Henry C. Pitot; Ronald L. Richardson; Bouwien J. Smits; Pitsata Sopapan; George Strang; Frank H. Valone; Stanimir Vuk-Pavlović
Clinical Trials
A Phase II Pilot Trial of Concurrent Biochemotherapy with Cisplatin, Vinblastine, Dacarbazine, Interleukin 2, and Interferon α-2B in Patients with Metastatic Melanoma1
David F. McDermott; James W. Mier; Donald P. Lawrence; Marcel R. M. van den Brink; Marquerite A. Clancy; Krista M. Rubin; Michael B. Atkins
Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinomas1
Margaret von Mehren; Philip Arlen; Kwong Y. Tsang; André Rogatko; Neal Meropol; Harry S. Cooper; Monica Davey; Susan McLaughlin; Jeffrey Schlom; Louis M. Weiner
Phase I Dose-finding and Pharmacokinetic Trial of Irinotecan Hydrochloride (CPT-11) Using a Once-Every-Three-Week Dosing Schedule for Patients with Advanced Solid Tumor Malignancy1
Henry C. Pitot; Richard M. Goldberg; Joel M. Reid; Jeff A. Sloan; Pam Atherton Skaff; Charles Erlichman; Joseph Rubin; Patrick A. Burch; Alex A. Adjei; Steven A. Alberts; Larry J. Schaaf; Gary Elfring; Langdon L. Miller
Imaging of Soft-Tissue Tumors Using l-3-[Iodine-123]Iodo-α-methyl-tyrosine Single Photon Emission Computed Tomography: Comparison with Proliferative and Mitotic Activity, Cellularity, and Vascularity1
Pieter L. Jager; Boudewijn E. C. Plaat; Elisabeth G. E. de Vries; Willemina M. Molenaar; Willem Vaalburg; D. Albertus Piers; Harald J. Hoekstra
Clinical and Biological Effects of Intraperitoneal Injections of Recombinant Interferon-γ and Recombinant Interleukin 2 with or without Tumor-infiltrating Lymphocytes in Patients with Ovarian or Peritoneal Carcinoma1
Ralph S. Freedman; Andrzej P. Kudelka; John J. Kavanagh; Claire Verschraegen; Creighton L. Edwards; Micheal Nash; Lawrence Levy; Edward N. Atkinson; Hua-Zhong Zhang; Bohuslav Melichar; Rebecca Patenia; Stacie Templin; Wanza Scott; Chris D. Platsoucas
Phase I Trial of Oral 2′-Deoxy-2′-methylidenecytidine: On a Daily × 14-day Schedule1
Noriyuki Masuda; Kaoru Matsui; Nobuyuki Yamamoto; Toshiji Nogami; Kazuhiko Nakagawa; Shunichi Negoro; Kouji Takeda; Nobuhide Takifuji; Masaji Yamada; Shinzoh Kudoh; Teruyoshi Okuda; Shinjiroh Nemoto; Kanako Ogawa; Hiroshi Myobudani; Shinichi Nihira; Masahiro Fukuoka
Molecular Oncology, Markers, Clinical Correlates
Relative Expression of Type IV Collagenase, E-cadherin, and Vascular Endothelial Growth Factor/Vascular Permeability Factor in Prostatectomy Specimens Distinguishes Organ-confined from Pathologically Advanced Prostate Cancers1
Hiroki Kuniyasu; Patricia Troncoso; Dennis Johnston; Corazon D. Bucana; Eiichi Tahara; Isaiah J. Fidler; Curtis A. Pettaway
Enhanced Urinary Gelatinase Activities (Matrix Metalloproteinases 2 and 9) Are Associated with Early-Stage Bladder Carcinoma: A Comparison with Clinically Used Tumor Markers1
Cornelis F. M. Sier; Giovanni Casetta; Jan H. Verheijen; Alessandro Tizzani; Vittorio Agape; Janko Kos; Francesco Blasi; Roeland Hanemaaijer
Detection by Denaturant Gradient Gel Electrophoresis of Tumor-specific Mutations in Biopsies and Relative Bronchoalveolar Lavage Fluid from Resectable Non-Small Cell Lung Cancer
Gianluigi Ferretti; Giuseppe Curigliano; Ugo Pastorino; Achille Cittadini; Giovanna Flamini; Maria Grazia Calabrò; Tommaso De Pas; Laura Orlando; Mario Mandalà; Marco Colleoni; Lorenzo Spaggiari; Pier Luigi Granone; Gabriella Pagliari; Filippo de Braud; Nicola Fazio; Aron Goldhirsch
Experimental Therapeutics, Preclinical Pharmacology
A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells1
Uwe Zangemeister-Wittke; Siân H. Leech; Robert A. Olie; A. Paula Simões-Wüst; Oliver Gautschi; Gerd H. Luedke; François Natt; Robert Häner; Pierre Martin; Jonathan Hall; Carlo M. Nalin; Rolf A. Stahel
Cancer Biology, Immunology, Cytokines
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.